Repurposing Drugs in Oncology (ReDO)—mebendazole as an anti-cancer agent
MetadataShow full item record
CitationPantziarka, Pan, Gauthier Bouche, Lydie Meheus, Vidula Sukhatme, and Vikas P Sukhatme. 2014. “Repurposing Drugs in Oncology (ReDO)—mebendazole as an anti-cancer agent.” ecancermedicalscience 8 (1): 443. doi:10.3332/ecancer.2014.443. http://dx.doi.org/10.3332/ecancer.2014.443.
AbstractMebendazole, a well-known anti-helminthic drug in wide clinical use, has anti-cancer properties that have been elucidated in a broad range of pre-clinical studies across a number of different cancer types. Significantly, there are also two case reports of anti-cancer activity in humans. The data are summarised and discussed in relation to suggested mechanisms of action. Based on the evidence presented, it is proposed that mebendazole would synergise with a range of other drugs, including existing chemotherapeutics, and that further exploration of the potential of mebendazole as an anti-cancer therapeutic is warranted. A number of possible combinations with other drugs are discussed in the Appendix.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:12717512
- HMS Scholarly Articles